Barcelona Liver Bioservices announces collaboration with Conatus Pharmaceuticals

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Conatus Pharmaceuticals, biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.

Under the terms of the agreement, which combines the scientific and technical expertise of both companies, BLB will perform cutting-edge research to understand the mechanisms underlying the beneficial effects of Conatus’ lead compound emricasan on liver cirrhosis and portal hypertension.

For more information about the services and research developed by BLB please visit

More News

Barcelona Liver Bioservices (BLB) starts operations

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

Read More »